BG Medicine Announces New Publication on Prognostic value of galectin-3 in heart failure patientsBG Medicine, a life sciences company focused on the discovery, development and commercialization of novel diagnostics, announced the publication* of a study on the predictive value of plasma galectin -3 levels in heart failure patients with reduced ejection fraction and received crmedicaltourism.com/pulmonary-hypertension-treatment.html .
The main findings of the Audit Report reveal the extent of the problem in the region, in most countries Significant increase in the number of elderly people and in to fragility fractures for most countries in the coming decades and no standards of care and lack of modern surgical treatment of after hip fracture patients in many countries, the disability itself in widespread high death rates, lack of epidemiological data on fractures and scientific research in the field of osteoporosis in many countries lack of official government approved national guidelines for osteoporosis and no formal fracture registries in many countries, vitamin D status and the average daily calcium intake is well below the wHO in most countries, those countries without reimbursement for medical treatment recommendations, treatment will remain out of reach for the majority the population Preliminary findings from the report were first presented at the IOF summit in Eastern Europe and Central Asia osteoporosis patient Societies in St. Petersburg, September 2010. National patient and medical societies discussed participation in the Summit, how the audit report can be effectively used as a tool advocacy advocacy in their countries, the public and health professionals awareness of the disease and promote research on osteoporosis and its impact in the region.
MetXia is Oxford BioMedica’s of lead Gen – based cancer treatment. The product has a highly developed retrovirus is that provides a specific human cytochrome P450 gene to tumor cells. Encodes the enzyme through the P450 gene is enabled the customarily used Crab chemotherapeutic, cyclophosphamide to damaged a form cells. MetXia converts the tumor in a ‘drug Fabrik ‘, so that the local output of the anti-tumor cytotoxic derivative is of the CPA. MetXia potentially be useful in the management of all fixed tumors and their metastases in particular those wherein Cyclophosphamide did proven efficacy.
For further information, please contact: Oxford BioMedica the PLC to Professor Alan Kingsman, Chief Executive Tel:+44 1865 783 000City / Financial requests Lisa Baderoon / Mark Court / Mary-Jane Johnson Buchanan Communications Tel:+ 44 20 7466 5000Scientific / Trade Press requests Sue Charles, Katya Stout,33 percent of the insurance patients in complete cost of some services, Pay, Survey Shows.